BCC 2021 | Genetic testing in breast cancer: who, what and why?

Judy Garber • 15 Mar 2021

BCC 2021

Breast Cancer Olaparib

OlympiA

Judy Garber, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, discusses predictive and prognostic genetic testing in breast cancer, outlining who should be tested, what genes should be investigated, and how the findings could guide treatment decisions. Prof. Garber talks on how the findings of the OlympiA trial (NCT02032823) of olaparib treatment in patients with germline BRCA1/2 mutations and high-risk HER2-negative primary breast cancer could change thinking on who should be tested. This interview took place during the 17th St. Gallen International Breast Cancer Conference

Disclosures

Prof. Garber reports being the co-PI of the OlympiA trial, supported by Astra-Zeneca/Merck, Co-PI of the BRCA-P trial, supported by AmGen and by a grant from the Department of Defense.

Prof. Garber reports research support from Myriad, Ambry and Invitae Genetics Laboratories, and unpaid consulting for Konica Minolta.